text:
Second cannabis dispensary opens in Marysville
Cannabis | June 17, 2019
Jake Abbott
Special to The Union
After months of delays, Marysville finally has both of its allowed-for medical marijuana dispensaries open for business.
By the end of the year, however, the city is looking to further expand its cannabis options, as officials consider allowing for recreational sales and delivery.
Wild Seed Wellness, located at 1109 Chestnut St., Marysville, opened a few weeks ago. Its products include flower, concentrates, edibles, tinctures and topicals, according to its Weedmaps profile.
The medical marijuana dispensary was originally slated to open in February or March but needed to update its facilities to meet certain city requirements.
"It was more about construction and meeting all the compliance issues, for them to get everything lined out on their end before they opened up," said Marysville Police Chief Chris Sachs.
Representatives from Wild Seed Wellness did not respond for comment.
The dispensary is the second to open its doors in the city this year. The first was Perfect Union — 311 F Street, Marysville — which opened in January. The city has already benefitted from the dispensary's operations, bringing in over $15,000 in fees since its opening, said City Manager Marti Brown.
The city is also looking at approving a cannabis testing lab within city limits. Brown said the development agreement for the facility will be discussed during today's city council meeting. If approved, the plan is for the facility — located at the corner of Fifth Street and C Street — to open at the beginning of July. The city would receive a monthly payment of 3% on gross receipts once operational.
State law requires that all marijuana is tested and labeled before being sold.
"The labeling is really important, so people know exactly what they are getting because it has been tested. Also, if anything goes wrong with the product, they can pinpoint where the batch came from," said Mayor Ricky Samayoa. "Bringing in the testing facility is going to be key for the cannabis industry moving forward in the area."
Recreational cannabis sales
Last month, city officials met with a consulting firm, HdL Companies, to discuss how the city could go about managing and regulating recreational sales. Samayoa said the majority of council members at the special workshop expressed their support of the idea of bringing commercial operations to the city.
The idea is to not expand the number of dispensaries, but allow the two currently in operation to also sell recreational products. Samayoa said the change of heart came about with the passing of Proposition 64 and the state adopting regulations for commercial cannabis operations.
"We now have regulations establishing the ground rules, so we are very clear on what everyone has to do in order to participate in the industry," he said.
Another idea officials are pondering is allowing cannabis delivery services within the jurisdiction. Companies are already providing delivery services through websites like Weedmaps and Leafly. Samayoa said without anything on the books to regulate this facet of the industry, law enforcement has little backing to hold the companies accountable, and it's ultimately undercutting the brick-and-mortar businesses.
"We also want to include language in the new ordinance regarding mobile dispensaries," Samayoa said. They would need to get a permit through the city if they want to do business in city limits. The folks that have invested in brick and mortar, they really are at a disadvantage when these other businesses are going unchecked.
"In many ways, we already have recreational cannabis available in the city, because of these delivery services. This way, we can have more regulations around it to make sure it's being done properly."
Brown said it's hard to say exactly how expanding to allow recreational sales would impact the city financially, though it would no doubt increase the amount of revenue being brought in. Any additional funds will prove to be critical as it could result in the city adding another maintenance worker, police officer or dispatcher, Brown said.
"To me, that's how I view the money, it might not be a lot but we have limited resources and staff capacity, and it could mean one more employee for departments that are in need of additional employees or to help with a one-time purchase of needed equipment," Brown said.
Despite the stigma that still surrounds the cannabis industry, Samayoa said, the city hasn't yet experienced any issues. It's the only jurisdiction in the Yuba-Sutter area that currently allows any type of sales.
"I think our residents who consume cannabis are benefiting because they have an accessible place that is safe with good products. It's not a judgmental thing anymore; people use cannabis, just like some people like to have a glass of beer or wine," Samayoa said. "I think, overall, it's been positive. We haven't' seen any negative effects, aside from having to deal with the mobile businesses, but hopefully this ordinance moves forward."
Brown said city staff will work with HdL this summer on rewriting the current ordinance to allow for recreational sales and delivery services. With a recess planned for August,city council members will likely take up the ordinance change during a September meeting.
Jake Abbott writes for the Marysville Appeal Democrat. He can be reached at jabbott@appealdemocrat.com.
The Union NOW!


text:
JSQA
CRO List
Clinical Research Jobs
ICH GCP | Clinical Trials Registry
Clinical Trials: SEARCH[Study] TILT[Study:StudyFirstPostDate] AREA[InterventionSearch] Placebo
Fill in any or all of the fields below.
Click on a label to the left for further explanation or read the Help.
Recruitment:
All Studies Open Studies Closed Studies Exclude Unknown Status
Study Results:
All Studies Studies With Results Studies Without Results
Study Type:
All Studies Interventional Studies Observational Studies Expanded Access Studies
Targeted search:
Interventions:
Outcome Measures:
Sponsor/Collaborators:
Sponsor (Lead):
Study IDs:
State 1:
--- Optional --- United States, Alabama United States, Alaska United States, Arizona United States, Arkansas United States, California United States, Colorado United States, Connecticut United States, Delaware United States, District of Columbia United States, Florida United States, Georgia United States, Hawaii United States, Idaho United States, Illinois United States, Indiana United States, Iowa United States, Kansas United States, Kentucky United States, Louisiana United States, Maine United States, Maryland United States, Massachusetts United States, Michigan United States, Minnesota United States, Mississippi United States, Missouri United States, Montana United States, Nebraska United States, Nevada United States, New Hampshire United States, New Jersey United States, New Mexico United States, New York United States, North Carolina United States, North Dakota United States, Ohio United States, Oklahoma United States, Oregon United States, Pennsylvania United States, Rhode Island United States, South Carolina United States, South Dakota United States, Tennessee United States, Texas United States, Utah United States, Vermont United States, Virginia United States, Washington United States, West Virginia United States, Wisconsin United States, Wyoming Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Quebec Canada, Saskatchewan Australia, Australian Capital Territory Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia Australia, Tasmania Australia, Victoria Australia, Western Australia
Country 1:
--- Optional --- United States Afghanistan Albania Algeria American Samoa Andorra Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Central African Republic Chad Chile China Colombia Congo Congo, The Democratic Republic of the Costa Rica Croatia Cuba Cyprus Czech Republic Côte D`Ivoire Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Estonia Ethiopia Fiji Finland Former Serbia and Montenegro Former Yugoslavia France French Polynesia Gabon Gambia Georgia Germany Ghana Greece Grenada Guadeloupe Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Korea, Republic of Kuwait Kyrgyzstan Lao People`s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Lithuania Luxembourg Macau Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Mali Malta Martinique Mauritania Mauritius Mexico Moldova, Republic of Monaco Mongolia Montenegro Morocco Mozambique Myanmar Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Northern Mariana Islands Norway Oman Pakistan Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Romania Russian Federation Rwanda Réunion Saint Kitts and Nevis Saudi Arabia Senegal Serbia Sierra Leone Singapore Slovakia Slovenia Solomon Islands South Africa Spain Sri Lanka Sudan Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tanzania Thailand Togo Trinidad and Tobago Tunisia Turkey Uganda Ukraine United Arab Emirates United Kingdom Uruguay Uzbekistan Venezuela Vietnam Virgin Islands (U.S.) Yemen Zambia Zimbabwe
Location Terms:
Additional Criteria:
All Studies Studies with Female Participants Studies with Male Participants
Child (birth-17) Adult (18-65) Senior (66+)
Phase:
Phase 1 Phase 2 Phase 3 Phase 4
NIH Industry
Other U.S. Federal Agency All others (Individual, University, Organization, ... )
Has an outcome measure designated as a safety issue.
First Received:
From To (MM/DD/YYYY)
First Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 … 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 Next Last
NCTID/Status
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
Conditions: ADHD; Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
Intervention: MG01CI (1400 Mg), Placebo
Twice Daily Oral ALLOD-2 vs. Placebo in the Treatment of Chronic Low Back Pain (ANODYNE-4)
Conditions: Chronic Low Back Pain; Lumbar Radiculopathy
Intervention: ALLOD-2 Capsules, Placebo Capsules
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
Conditions: Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
Intervention: BGG492, Placebo
Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder
Conditions: Pathological Gambling; Gambling Disorder; Opioid Antagonist; Naloxone
Intervention: Naloxone Hydrochloride, Placebo
Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin
Conditions: Neck Pain; Back Pain; Spasm
Intervention: Cyclobenzaprine HCl, Placebo
Unknown status
TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI
Conditions: ST Elevation Myocardial Infarction
Intervention: Ticagrelor, Placebo
Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms
Conditions: Parkinson Disease; Dyspepsia
Intervention: DA-9701, DA-9701 Placebo
Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
Conditions: Acute Pharyngitis; Sore Throat
Intervention: Flurbiprofen, Placebo
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Conditions: Psoriatic Arthritis
Intervention: Placebo For Rizankizumab, Risankizumab
Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine
Conditions: Acute Migraine
Intervention: Acetaminophen 250 Mg And Aspirin 250 Mg, Placebo
Selenium as Augmentation Treatment for Sertraline Resistant Major Depression
Conditions: Major Depression
Intervention: Selenium Supplementation, Placebo
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Conditions: Pulmonary Arterial Hypertension
Intervention: Inhaled Nitric Oxide 75 Mcg/kg IBW/hr, Placebo
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
Conditions: Respiratory Distress Syndrome, Adult
Intervention: Interferon Beta-1a, Placebo
HAL-MPE1 First-in-human
Conditions: Peanut Allergy
Intervention: HAL-MPE1, Placebo
Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Budesonide / Formoterol, Placebo
Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients
Conditions: Plaque Psoriasis
Intervention: Secukinumab, Placebo
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Conditions: Diabetes Mellitus, Type 2
Intervention: Semaglutide, Placebo (semaglutide)
Vascular Effect of Estrogens Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery
Conditions: Unspecified Injury of Brachial Artery, Left Side, Initial Encounter
Intervention: Estrogens, Conjugated (USP), Placebo
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
Conditions: Migraine
Intervention: Placebo ZNS, ZNS
Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion
Conditions: Chalazion
Intervention: SUN-131 1.5% TDS, Placebo TDS
Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode
Conditions: Suicidal Ideation/Behavior; Depression
Intervention: Lithium Carbonate, Placebo
The Effect of Oxytocin on Placebo Analgesia: an Experimental Study in Healthy Volunteers
Conditions: Mechanisms and Modulators of Placebo Analgesia in Healthy Volunteers
Intervention: Oxytocin, Placebo
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment
Conditions: Stroke; Cognitive Impairment
Intervention: Galantamine, Placebo
Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea
Conditions: Irritable Bowel Syndrome With Diarrhea
Intervention: Chang'an I Recipe, Placebo
Efficacy, Safety, and Tolerability of Twice Daily Oral ALLOD-2 vs. Placebo in Episodic Migraine Prevention (ANODYNE-3)
Conditions: Migraine With or Without Aura
Open-Label Placebos to Treat Fatigue in Multiple Sclerosis
Conditions: Multiple Sclerosis; Fatigue
Intervention: Treatment Group, No Treatment Group
Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain
Conditions: Breast Cancer; Lymphoma; Pain
Intervention: Pregabalin, Placebo
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
Conditions: Sexual Dysfunctions, Psychological
Intervention: Flibanserin, Placebo
Trial To Evaluate the Efficacy of Oral Salsalate in the Treatment of Older Adults With Unexplained Anemia
Conditions: Anemia
Intervention: Salsalate, Placebo
Spirulina Supplementation and Cardiovascular Risk in Obese Caucasians With Treated Hypertension
Conditions: Obesity
Intervention: Spirulina, Placebo
RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer
Conditions: Small Cell Lung Carcinoma
Intervention: Roniciclib (BAY1000394), Placebo
Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects
Intervention: AMG 333, Placebo
Potassium Oxalate and Placebo and Post-bleaching Sensitivity
Conditions: Medicaments Substances in Therapeutic Use
Intervention: Potassium Oxalate 5% Gel, Placebo Gel
Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis
Conditions: Mild to Moderate Ulcerative Colitis
Intervention: ORE1001, Placebo
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
Conditions: Chronic Urticaria; Chronic Idiopathic Urticaria; Chronic Spontaneous Urticaria
Intervention: Omalizumab (Xolair), Placebo
Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
Conditions: Psoriasis
Intervention: Aminopterin Oral Capsule, Placebo Oral Capsule
A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder
Conditions: ADHD; Attention Deficit Hyperactivity Disorder
Intervention: Naltrexone, Placebo
A Dietary Supplement for Mood Symptoms in Early Postpartum: A Double Blind Randomized Placebo Controlled Trial
Conditions: Postpartum Blues; Healthy
Intervention: Motherwell, Placebo
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
Conditions: Pre Diabetes; Polycystic Ovary Syndrome; Obesity Android
Intervention: Liraglutide Pen Injector [Saxenda], Placebo Liraglutide Pen Injector
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
Conditions: Alzheimer's Disease; Dementia
Intervention: Drug: NIC5-15, Placebo
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
Conditions: Primary Sjögren's Syndrome
Intervention: Baminercept, Placebo
A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
Conditions: Lymphedema; Lymphatic Filariasis; Filariasis
Intervention: Doxycycline, Placebo
Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome
Conditions: Diastolic Heart Failure
Intervention: Perhexiline, Placebo
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Conditions: Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Intervention: CB-839, Cabozantinib, Placebo
STIP: Statin Trial for Influenza Patients
Conditions: Acute Respiratory Distress Syndrome; Influenza; H1N1 Influenza
Intervention: Rosuvastatin (crestor), Placebo
The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study
Conditions: Alzheimer Disease
Intervention: MLC901, Placebo
Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants
Conditions: Prevention of Growth Restriction
Intervention: RhBSSL (recombinant Human Bile-salt-stimulated Lipase), Placebo
MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)
Conditions: Alcohol Withdrawal Syndrome
Intervention: Magnesium, Placebo Oral Tablet
Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease
Conditions: Interstitial Lung Disease; Dyspnea; Morphine
Intervention: Morphine Hydrochloride, Placebo
The last updated date is the most recent date when changes to a clinical trial were submitted to ClinicalTrials.gov. There is often a delay of a few days before the updated trial is available on the clinical trials website.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
First Received
The first received date is the date when the clinical trial was first submitted to ClinicalTrials.gov. There is often a delay of a few days before the trial is available on the clinical trials website.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
If selected, restricts search results to those studies which have an outcome measure designated as a safety issue. Note that this is a poor estimate of the safety of a treatment or intervention, but it is all we have now.
Studies are supported by one or more organizations called sponsors. Support includes contributions of facilities, expertise, and/or financial resources. All sponsors in the database have been assigned one of the following organization types:
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Studies may be designed for participants of particular ages:
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Searches can be restricted to studies which accept female or male participants.
Location Terms
If you are interested in a specific city (such as Los Angeles) or facility name (such as the Mayo Clinic), enter it as a location term. Not all studies include this level of detail, but if they do, this will find them.
Countries and States
Trials are often conducted at many locations around the world. Select up to three locations to find trials conducted in specific countries. Some countries (currently limited to the United States, Canada, and Australia), locations can be narrowed further by selecting a state.
Study IDs
Each trial is assigned one or more identification numbers by the institute, agency, or organization sponsoring the trial. In addition, clinical trials assigns a unique NCT identifier of the form NCTxxxxxxxx where each x is a numeric digit. Use this box to search for a trial by NCT identifier or any other study identification numbers.
97-h-0197
ia0006
actg 076
Sponsor (Lead)
Use this box to specify the name of an institute, organization, or company that is conducting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Sponsor/Collaborators
Use this box to specify institutes, organizations, or companies that are conducting or otherwise supporting a trial.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Outcome measures are used to evaluate trial results. For example, an obesity treatment might be evaluated by a measure of weight loss after 6 months. Measures can also be used to quantify side effects, such as number of myocardial infarctions, number of patients with heart arrhythmia, number of suicides, etc.
Use this box to specify an outcome measure used to evaluate trial results.
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied. Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
clofibrate
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov, conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Use this box to specify the conditions being studied.
risk factors for breast cancer
There are three types of studies available in ClinicalTrials.gov:
Interventional:
Studies where individuals are assigned to receive specific interventions. Participants may receive diagnostic, therapeutic or other types of interventions. Assignment of the intervention may or may not be random. Individuals are tracked and biomedical and/or health outcomes are assessed.
Observational:
Studies without an intervention. Studies where biomedical and/or health outcomes are assessed in a pre-defined group of individuals. Participants may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the participants of the study.
Expanded Access:
Records describing the procedure for obtaining an experimental drug or device for patients who are failing on currently available treatments for their condition and also are unable to participate in ongoing clinical trials. Expanded Access records are used to register all types of non-protocol access to experimental treatments, including protocol exception, single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track.
Searches can be restricted to studies with or without results.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
Recruitment Status
Also known as Enrollment Status.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Values are color coded (as shown) in the search results.
Use this box to specify general search terms found anywhere in the trial record.
Multiple terms can be separated by an AND (all uppercase).
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Help for Searching clinical trials
Help Topics:
Search Expressions
Basic Search:
On the Basic Search page, enter a word or word(s) that you want to use to find studies. These may include diseases, interventions, and/or locations.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
Use of a Pacemaker Following a Heart Attack.
higher than the study,
Heart Defects and Transient Ischemic Attacks
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Many searches are a single term and can be performed with a few words in the search box. But, sometimes you need more control. Click on the Advanced Search tab (if starting a new search) or Refine Search tab (if modifying an existing search) to show additional search fields.
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Performs a general search in all sections of the study record, including title, description, conditions, interventions, locations, etc. Terms in this field are searched the same as Basic Search.
Limits search results to studies that are open or closed. New volunteers may be able to participate in open studies, but not closed studies.
Limits search results based on whether the study has results or not:
All Studies,
Studies With Results, or
Studies Without Results
The inclusion of Study Results is a new feature of ClinicalTrials.gov. Only a few studies have results available.
Limits search results to any of the following study types:
Interventional,
Observational, or
Performs a search on fields describing the diseases or conditions being studied.
Performs a search on fields listing the drugs or interventions being studied.
Outcomes Measures:
Performs a search on fields listing the outcome measures used to quantify study results.
Performs a search on fields listing the sponsor and collaborators of a study.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Performs a search on the sponsor field of a study.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Performs a search on fields listing ID numbers.
Trials are often conducted at many locations around the world. Select up to three locations to find trials conducted in specific countries. Some countries (currently limited to the United States, Canada, and Australia), locations can be narrowed further by selecting a state (e.g., United States, Alabama).
Finds studies in specific locations such as a city (Los Angeles) or facility (Mayo Clinic). Not all studies include this level of detail, but if they do, this will find them.
Limits search results to those studies that accept female or male participants.
Limits search results to those studies that include at least one of the specified age ranges. More than one age group can be selected.
Limits search results to studies that are labeled with at least one of the specified phases. More than one Phase can be selected.
Limits search results to studies that have at least one sponsor of the specified types. More than one sponsor type can be selected.
Limits search results to studies that have at least one outcome measure designated as a safety issue.
Limits search results to studies that were received by clinical trials within a specified date range. The "From" or "To" field can be left blank.
Limits search results to studies that were modified within a specified date range. The "From" or "To" field can be left blank.
Searches display a list of studies found (List Results tab). If you are not content with the search results, click on the Refine Search tab at the top of the list to modify your search.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
When you are done making changes, click Search to display the new results.
Search Expressions:
Use AND (all upper case) to find study records that contain all terms connected by AND.
prostate cancer AND radiation
heart disease AND stroke AND California
Use OR (all upper case) to find study records that contain either term connected by OR.
Aspirin OR ibuprofen
heart disease OR heart attack
Use NOT (all upper case) to find study records that do not contain the term following NOT.
Immunodeficiency NOT AIDS
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
prostate cancer AND NOT ( radiation OR homeopathic remedies )
( heart disease OR heart attack ) AND ( stroke OR clot )
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
Ear, Nose, and Throat Conditions
is the expression
( Ear OR Nose OR Throat ) AND Conditions
Fortunately, search will do a pretty good job of finding the right studies either way.
To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.
Clinical Trial Assistant
Drug Safety Associate E/L
Sr. Director, Project Management - Women's Health (Home-based)
Quality Assurance Auditor 1 - GLP Tox
Shrewsbury, MA, US, 01545
Malvern, PA, US, 19355
Clinical research organizations
Clinical Research Management Group
Symphony Pharma Life Sciences
Dishman Group
Max Neeman
FGK Clinical Research
Alphabetic (A-Z)
Sponsor/
Clinical Trails
© ICH GCP. All Rights Reserved.

redpajama_set_name: RedPajamaCommonCrawl


text:
Home News 'The skills gap is a moving target' says LinkedIn's Allen Blue
'The skills gap is a moving target' says LinkedIn's Allen Blue
The LinkedIn co-founder tells WorkingNation's Ramona Schindelheim that his company is applying data-driven solutions to accelerate the closure of the skills gap.
Ramona Schindelheim
Allen Blue, LinkedIn Co-founder with WorkingNation Founder Art Bilger at the 2017 Milken Institute Global Conference. Photo – Jonathan Barenboim
WorkingNation Executive Producer and Senior Business Correspondent Ramona Schindelheim continues her series of interviews with top executives on how their companies are taking on the problem of the skills gap.
Photo – Shutterstock
LinkedIn is in the business of connecting jobs with people and people with jobs. Anyone familiar with the social media platform knows that companies use it to post job openings, listing the skills and experience they're looking for to fill an open position. Job seekers use it to post their CVs, listing the skills and experience they have. If the opening and skills align, it could lead to a job match.
With 500 million members worldwide, LinkedIn also has collected a lot of valuable information about the overall state of the job market, and they want to use it to help speed up finding solutions to closing the skills gap.
"At LinkedIn, what we're seeing is a snapshot of the moment. We have a good idea of who's out there and what skills they've got. We also have pretty good visibility into new jobs as they appear," according to Allen Blue, the co-founder of LinkedIn and its Vice President of Product Management. (Full disclosure: Blue is also a member of WorkingNation's executive committee.)
Blue says that information gives his company a real-time, deep-dive look at the talent gap. "We have the ability to look at the information and say, for instance, the biggest single skill gap in Denver is among medical records technicians. That's a place where the need is very high, and the supply is low. And in those cases, what we need to say is, 'Hey, can we possibly light up training quickly to take advantage of those openings?'," Blue says.
The problem, Blue tells me, is that the connection between the need for skilled workers and training solutions is not happening fast enough. The whole cycle of first bringing together businesses with educators, and then with workers, can take as long as two, even three years. "The skills gap is a moving target. We want to get to the place where, within weeks of new skills being required, we can detect a gap, and we can put the employer directly together with the educator."
"The thing that makes LinkedIn potentially powerful is that we already bring the employers and the individuals together at that place. And if the educators join that group, then we have all the participants together in one spot. We can actually build a marketplace which hooks the three together," says Blue.
He says a platform like LinkedIn could theoretically allow employers to signal directly to local educators with no lag time. "We want to make sure that employers have a simple mechanism for signaling what they need, for individuals to talk about what they actually know about, and then for schools to talk about how they can fill in the gaps in skills."
RELATED STORY: The State of Work: Michigan Gov. Rick Snyder launches 'Marshall Plan for Talent'
Blue says the only way to solve the skills gap of the size now facing the United States is to work with every employer, no matter its size, and with every educator. "The economy is a big, complex system. And there's no one person; there are not even going to be one, or two, or three, or four persons or entities you can go to attack a problem of this scale and complexity. Do it together with everybody."
LinkedIn, like many other companies, is struggling to hire tech workers of its own. While Silicon Valley is a mecca for software engineers, everyone is fighting for a pool of skilled workers that is just too small.
Last year the company started a six-month pilot apprentice program called REACH to help fill the talent shortage. More than 700 people applied. The goal, according to LinkedIn, was to tap into a talent pool of people passionate about computer science but who came by their initial programming training in a non-traditional way.
83 percent of REACH's inaugural cohort was employed by LinkedIn or another software company. Photo – LinkedIn
"We brought in 30 people who had come from different careers, and some came right out of school. All of them had some limited coding training, but not a Computer Science degree. They had taken a General Assembly course, or they had gone to community college and learned it there," says Blue.
The apprentices included people with marketing backgrounds and some who had run their own businesses. All were looking to transition into a career in programming.
They were each assigned to a specific team with a manager who individually coached and mentored them. They were given hands-on training in jobs which delivered products to LinkedIn members. At the end of the six months, the managers evaluated the apprentices on their performance and their potential to continue their training to become software engineers.
LinkedIn hired 24 of the apprentices and another one got a job at a different company. They were hired in a variety of roles, including web development and mobile app development.
Eventually, according to Blue, he believes the new hires will end up as front-end software engineers. "That's a pretty good investment on our part, and it's worth our doing that because we need the people."
Blue tells me LinkedIn wants to set an example for other companies struggling to find skilled employees.
"Every time there's a skills gap, and there's not just one skills gap at the moment, there are opportunities which come from them. There are opportunities for companies to invest, to create the next collection of software engineers, or medical records technicians or advanced manufacturing workers," Blue says. "Those opportunities are there because the company really need them, and companies are willing to invest. Every company that's on the losing end of the skills gap, who says "I can't hire people I need," can become a force for training them, for changing the face of the American worker."
WATCH: Blue participated in WorkingNation's panel "Unbound: Retraining the American Workforce" at the 2017 Milken Institute Global Conference which you can watch below.
Join the Conversation: We invite you to share your thoughts on how LinkedIn is working to close the skills gap on our Facebook page.
Catch up on previous C-Suite Solutions stories here.
Connect with Ramona via Twitter or her website. You can read her previous articles for WorkingNation at this link.
Allen Blue
C-Suite Solutions
Talent Gap
Previous articleHelp yourself by overcoming your resistance to assistance
Next articleStarting Out in Tech: Why you should pick up Python skills first
https://www.ramonaschindelheim.com/
Women in Tech: Cultivating Diversity
Should you "love" your job?
GradNation: 90% High School Graduation Rate Would Add 65,000 New Jobs...
New Study: Increasing apprenticeships will lead to more companies saying "You're...
Raising the Profile of Careers in STEM Fields
Get to know WorkingNation President Jane Oates
Cuarón's 'Roma' gives heart to profession in crisis
Adaptability needs to replace fear in the future of work
Organization Shows Great Success Getting At-Risk Students Career Ready
Community colleges and Amazon team up for cloud computing certification training
Penny Pritzker at ASU + GSV Summit: We need a generation...


text:
contact@youthofamerica.org
Youth Of America
Free Game Downloads & News
How To Get Games For Free
July 3, 2018 December 1, 2018 Hector Clark
Getting games for free is often a touchy subject for most gamers since it can be connected to piracy and theft. However, there are quite a lot of ways to get free games legally. It requires some luck and patience, but free games are a thing and they can allow players to play without breaking the bank.
Keep in mind that all of these methods are supported by developers and are legal. Piracy and torrenting games are crimes, however, both physically and ethically.
Wait for giveaways
Steam giveaways, coupons, and bundle sales all happen pretty regularly on sites such as Steam and Humble Bundle where games are given away for free. For an example, some steam coupons reward the owners of certain games with others in the same genre.
Bundle sales can bundle a group of popular and similar games together and offer them for low amounts of money (usually around ten dollars.) If buyers play their cards right, several games and even several bundles can be received with the same cost of a triple-A title.
Other giveaways can happen with companies and developers, while it isn't uncommon to have games be given away for free on certain occasions, and trackers can help email notifications of sales and giveaways to potential players be caught and taken advantage of.
Use free to play games.
While most of these games are MMO's and have microtransactions or DLC to support them financially, there is a good variety of both single player and multiplayer games out there in the world that is for free. World of Warcraft, Dwarf Fortress, and Quake are all good examples of fun and time-consuming games that don't cost a dime.
In addition, various apps and mobile games are free with optional in-game purchases like Clash of Clans, Hay Day, and Fortnite. These games are addicting, fun, and can be played from anywhere without spending any money.
Look for databases and emulators
While this is mostly for out of publication and older games, or indie titles that want to make a name for themselves, game databases and libraries often have older games from years gone by that can either be downloaded or played directly in the browser.
Emulators also exist for out of publication game models like Gameboys or classic arcade games and can allow for games on these out of date machines to be played on modern hardware. These websites are legal and are often open about their legality, making them safe to download and play on.
There are countless open source games and free to play games and apps that can tide gamers over until the next giveaway or cheap bundle appears for the games they desperately want, and all it takes is a little research and investigation.
It does take a little luck and a lot of patience if gamers rely on giveaways and bundles, but for those who stick it out, know that almost any game goes through a free to play phase.
Difficulty and Dwarves: Dwarf Fortress
I'm Hector Clark – and welcome to Youth of America – your one stop source for the latest free game downloads, updates, trends and news. Read our latest post by clicking here.
HAVE YOU SHARED?
Download games fortnite Gaming online Gaming portal Online Gaming
https://www.youtube.com/watch?v=FehINTf9a_4
How Free Games Still Make Millions
Surviving the Cataclysm: Cataclysm Dark Days Ahead
Copyright All rights reserved | Managed by Youth Of America


text:
FERGIE'S OUT
Sir Alex Ferguson leaves hospital less than a month after Manchester United great suffered a brain haemorrhage
Fergie is being nursed back to health by loved ones and hopes to be back at Old Trafford for the start of the new season
Guy Patrick
SIR Alex Ferguson is out of hospital less than a month after emergency brain surgery.
The Man United legend, 76, is now being nursed back to full health by his loved ones.
Sir Alex Ferguson is out of hospital following brain opCredit: Reuters
And he has told his inner circle he hopes to be back in his seat at Old Trafford for the start of the season in August.
A source said: "Everyone knows Sir Alex is a winner and this was one battle he was never going to lose.
"He's back on his feet and glad to be out of hospital, though he couldn't be more grateful to the staff.
"The prognosis is extremely promising and it'll only be a matter of time before he's back at the 'Theatre of Dreams'.
Dream Team World Cup - Sign up to win £100k
Enter for FREE
£50m budget and 20 transfers throughout the tournament
Play to win £100k top price and a share of £175k prizepot
SIGN UP FOR DREAM TEAM WORLD CUP NOW
Sir Alex, with wife Cathy, is being looked after by loved ones following surgeryCredit: AFP and licensors
"Meanwhile he can put his feet up and enjoy the World Cup."
Fergie was placed in an induced coma at Salford Royal Hospital on May 5 after suffering a brain haemorrhage.
The Sun revealed his first words when he came round were: "How did Doncaster get on today?"
Son Darren's team lost 1-0 to Wigan as Sir Alex was in the operating theatre.
David Beckham talks about health of Sir Alex Ferguson on Graham Norton
Well-wishers send a message to the footballing legend
Fergie asked how son Darren's team Doncaster got on after coming roundCredit: PA:Empics Sport
Sir Alex was being treated at Salford Royal InfirmaryCredit: REUTERS
He even joked to family at his bedside about making it to see Liverpool in last week's Champions League final in Kiev.
A United spokesman said they would not be providing updates on Sir Alex's condition.
GOT a story? RING The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or EMAIL exclusive@the-sun.co.uk
Sir Alex Ferguson 'will pull through', insists Manchester United legend Eric Cantona


Thank you, Mr. Chairman. I would like to join you in welcoming our nominees. Thank you both for your willingness to serve in positions of great responsibility in the Department of Defense. I would also like to thank your family members who, like all military families, sacrifice so much for the security of our nation.
I also note with a heavy heart the loss of U.S. Fifth Fleet commander Vice Admiral Scott Stearney over the weekend. On behalf of the entire Committee, I extend our condolences to his friends, family, and all who knew him.
The guidance contained in the NDS is likely to result in significant changes to the commands you have been asked to lead. With respect to U.S. Central Command (CENTCOM), the NDS forecasts reduced force structure and more efficient utilization of what remains. Managing the implementation of those changes and any impact they may have on our ability to carry out counterterrorism operations, deter Iran, and reassure our allies and partners will be significant considerations for CENTCOM in the coming years.
With respect to U.S. Special Operations Command (SOCOM), the focus of the NDS raises questions about the role of special operations forces in the competition with potential near-peer adversaries. Given that special operations forces have been heavily committed to the fight against violent extremist groups since 9/11, SOCOM will necessarily have to evaluate whether its current capabilities are appropriately matched to the operations its forces will be asked to conduct in the future. Additionally, given the already high operational tempo on special operations forces, SOCOM will need to be careful that any additional responsibilities do not overstress the force. I hope both of our nominees will discuss the expected impact of the NDS on the Commands they have been nominated to lead and how any challenges can be mitigated in implementation.
Last week we held a hearing with the National Defense Strategy Commission to discuss their review of the NDS. The Commission's report states that there is a "relative imbalance of civilian and military voices on critical issues of strategy development and implementation." It goes on to state that "civilian voices were relatively muted on issues at the center of U.S. defense and national security policy, undermining the concept of civilian control." When I read the Commission's report, I was struck by these observations and the consequences that such an imbalance could have on the development of defense policy, the impact it could have on the civilian and military personnel serving in the Department, and how it may shape the advice provided to the President. As senior members of the Joint Staff, I hope both of our nominees will share their thoughts on the Commission's finding and how their experience with civilian policymakers would shape their leadership of CENTCOM and SOCOM, respectively.
On this point, the committee focused attention in recent years on strengthening the partnership between the SOCOM Commander and the Assistant Secretary of Defense for Special Operations and Low-Intensity Conflict, or ASD SOLIC. In particular, section 922 of the National Defense Authorization Act for Fiscal Year 2017 enhanced the role of ASD SOLIC to serve as the "service secretary-like" official responsible for oversight of, and advocacy for, special operations forces. General Clarke, I look forward to hearing your views on the implementation of these reforms and how the ASD SOLIC – SOCOM partnership can be further strengthened.
Again, I thank you for your willingness to serve and I look forward to your testimony. Thank you, Mr. Chairman.


The information revolution is drawing to a close as our expanding information resources bury decisions under ever-higher piles of conflicting data. Leaders of even small organizations simply cannot tell what matters.
The reason for this is our neglect of relevance as raw data get cheaper to generate. To learn from experience despite the glut of information, we must define relevance in a new way — and one that depends critically on assumptions.
More specifically, we must develop strategies explicit enough to be testable, derive performance metrics from the assumptions behind those strategies, and use performance results to reveal errors in our strategic goals and assumptions as well as in execution.
The testable strategies, relevant metrics, and strategy reviews proposed here amount to more than a guide for coping with performance information overload. They embody an experimental approach to management and problem solving. It's an approach that reflects a thorough fallibilism about the strategies we construct to meet our goals and an optimism that we can always do better.


text:
package net.codemap.carousel.components;

import javax.swing.*;
import javax.swing.border.LineBorder;
import javax.swing.event.ChangeEvent;
import javax.swing.event.ChangeListener;
import java.awt.*;

/**
 * Demo program showing ScalableImage's capabilities
 *
 * @author Anthony Benavente
 * @version 5/4/15
 */
public class ScalableImageTest extends JPanel implements ChangeListener {

    /**
     * The image that is drawn to the screen
     */
    private ScalableImage image;

    /**
     * Controls the width of the image
     */
    private JSlider widthSlider;

    /**
     * Controls the height of the image
     */
    private JSlider heightSlider;

    /**
     * Sets up the panel that is on the JFrame
     */
    public ScalableImageTest() {
        setLayout(new BorderLayout());
        add(createImagePanel(), BorderLayout.CENTER);
        add(createControlPanel(), BorderLayout.SOUTH);
    }

    /**
     * Creates the panel that has the sliders for width/height
     *
     * @return the newly created panel for sliders
     */
    private JPanel createControlPanel() {
        JPanel result = new JPanel();

        widthSlider = new JSlider(0, 800);
        heightSlider = new JSlider(0, 500);

        // To see what the sliders do, see the implemented method in this class
        widthSlider.addChangeListener(this);
        heightSlider.addChangeListener(this);

        result.add(new JLabel("Width:"));
        result.add(widthSlider);
        result.add(new JLabel("Height:"));
        result.add(heightSlider);

        return result;
    }

    /**
     * Creates the panel with the image
     *
     * @return the newly created panel containing the scalable image
     */
    private JPanel createImagePanel() {
        JPanel result = new JPanel();
        image = new ScalableImage("res/img/example1.png", 400, 400);
        image.setBorder(new LineBorder(Color.gray));
        result.add(image);
        result.setBorder(new LineBorder(Color.black));
        return result;
    }

    /**
     * Called when any of the sliders are changed. The image's dimensions are
     * updated here.
     *
     * @param e the event fired from the sliders
     */
    @Override
    public void stateChanged(ChangeEvent e) {
        image.setWidth(widthSlider.getValue());
        image.setHeight(heightSlider.getValue());
    }

    /**
     * Entry point to the demo
     *
     * @param args Unused
     */
    public static void main(String[] args) {
        JFrame frame = new JFrame("Scalable Image Test");
        frame.setSize(800, 600);
        frame.setContentPane(new ScalableImageTest());
        frame.setDefaultCloseOperation(WindowConstants.EXIT_ON_CLOSE);
        frame.setLocationRelativeTo(null);
        frame.setVisible(true);
    }

}

redpajama_set_name: RedPajamaGithub


text:
Eretmotus peyerimhoffi är en skalbaggsart som beskrevs av André Théry 1917. Eretmotus peyerimhoffi ingår i släktet Eretmotus och familjen stumpbaggar. Inga underarter finns listade i Catalogue of Life.

Källor

Stumpbaggar
peyerimhoffi

redpajama_set_name: RedPajamaWikipedia


The controlled landfill is still one of the major solution to waste disposal. This kind of installation is strictly connected to the environment due to its polluting emissions, that can modify the land organization and roles; considering its dimensions and morphology, a waste disposal installation can have new bearings on the landscape main features.
The landfills built in the past often need reclamation interventions which can coexist with the development of disposal activities that nowadays hinge on up-to-date integrated waste management and land planning, which aim to the integration of the landfills into the urban structure meant as the whole of places of public interest.


text:
The A.I. Age
Pet insurance company Trupanion hit with a $100,000 fine
June 25, 2019 at 6:06 pm Updated June 26, 2019 at 3:32 pm
An employee at Trupanion's headquarters in Georgetown walks with her dog towards her cubicle to start the day. (Ellen M. Banner / The Seattle Times, file)
Keerthi Vedantam
Seattle Times business reporter
Seattle-based pet insurance company Trupanion was hit with a $100,000 fine by Insurance Commissioner Mike Kreidler's office, the third time in four years it has been sanctioned by the regulator.
Trupanion Managers USA, a unit of the publicly traded company, was fined for several marketing tactics: Exceeding the $100 limit in gifts in exchange for referrals, paying an unlicensed website to market pet insurance and generate leads, and paying $245,000 to five unlicensed representatives to sell pet insurance policies to veterinary clinics and animal shelters.
Kara Klotz, a spokeswoman for the insurance commissioner, said the regulations require insurers to work with licensed agents.
"If you're working with an unlicensed professional and they do something bad that harms you, we don't have recourse," she said. "If your (licensed) producer has violated state laws, you can go on our website and see exactly what they did."
It's not the company's first violation. In 2016, Trupanion Managers was fined $150,000 for obtaining $3.3 million in premiums through unlicensed producers. That same year, its sister company, American Pet Insurance Co., was fined $250,000 for charging inconsistent rates and mishandling consumer complaints.
"I would say it's not incredibly common for us to have follow-up actions," Klotz said. "We don't want to have to keep fining them."
Trupanion agreed with the insurance commissioner's claims, calling the errors clerical mistakes.
Trupanion CEO Darryl Rawlings said the company paid a veterinary clinic $133 in gifts, which went over the maximum $100 allowed by the commissioner's office.
"That was a mistake on our part," Rawlings said. "We totally knew the rules."
The company paid Reviews.com, a website which the commissioner called an unlicensed producer. In a statement, Reviews.com said it supplies independently researched information on various topics and earns commissions when consumers click through to affiliated vendor sites.
"This one website was providing a level of detailed information that requires a license," Rawlings said. "We were not aware of that. We would have told them they're not allowed to do it. In that case it was an oversight on our side."
Trupanion is also working to license some of the unlicensed marketing representatives.
The fines won't make a huge dent in Trupanion's bottom line. The company's total revenue in 2018 was $304 million, a 24.7% increase from the previous year. And while the company still didn't break even last year, market analyst Kevin Kim Ellich said the company is still in a healthy spot.
"As they make more money, they're spending more money on pet acquisition cost," Ellich said. "A lot of that is just building brand awareness, helping educate pet owners about pet insurance and the benefits…given the low penetration rate of the pet market, I think Trupanion should be able to grow their top line."
The insurance commissioner's spokeswoman said these aren't the sorts of infractions that could cause a company to lose its license.
"We typically don't take that kind of action unless something really egregious is going on," Klotz said. "We want consumers to be able to be able to find insurance and for the market to thrive."
This story has been updated to clarify Review.com's role.
Keerthi Vedantam: 206-464-3226 or kvedantam@seattletimes.com; on Twitter: @keerthivedantam.
Most Read Business Stories
Protesters in Seattle petition Amazon to stop selling technology to ICE
How a tax loophole is helping tech company workers save millions
Boeing jet trouble leads to cuts at Europe's busiest airline
Meet the marrot, Arby's answer to plant-based 'meats' VIEW
We've just lived through the greatest period of restaurant growth in U.S. history. Here's why it's ending.


MLS week 31 average attendance is 22,132 compared to 26,122, last week. The regular season average has increased 0.09% to 21,562 from 21,542 last week. Stadiums were 90.59% filled throughout the week, staying at 89.58% of capacity for the season.
Five matches were sold out this week— Seattle Sounders FC versus Colorado Rapids at CenturyLink Field, D.C. United versus Montreal Impact FC at Audi Field, Minnesota United FC versus New York City FC at TCF Bank Stadium, Portland Timbers versus FC Dallas at Providence Park, and Sporting Kansas City versus Real Salt Lake at Children's Mercy Park.
What do you think about Major League Soccer's Week 31 attendance statistics? Let us know in the comments section below or on Facebook and Twitter.


text:
Home Latest Top British Don Lauds Peterside's Book on Maritime Mgt
Top British Don Lauds Peterside's Book on Maritime Mgt
Dakuku Peterside
A British Professor, Chris Bellamy, has applauded a yet-to-be-released book published by a former Director General of the Nigerian Maritime Administration and Safety Agency (NIMASA), Mr. Dakuku Peterside.
The book, "Strategic Turnaround", he said, gives a definitive case of successful high-level change management and essential insight into the maritime sector of an emerging maritime power.
A statement by the General Manager, Safari Books Limited, Ibadan, Olayemi Onakunle, quoted Bellamy as positing that the book showcased the radical reform of the NIMASA and the entire maritime sector in Nigeria by its leaders and key stakeholders.
"The story of how strategic change was initiated, instigated, and successfully managed in the maritime sector in Nigeria has far-ranging relevance within the horn of Africa and beyond.
"This story is briefly and eloquently told in Strategic Turnaround," Bellamy stated.
He added that the country's maritime sector is highly significant, having Africa's largest economy and the 24th in the world, with a Gross Domestic Product (GDP) estimated by the International Monetary Fund (IMF) at about $500 billion. "Nigeria's maritime sector is of great importance, not only for indigenous transport but potentially globally," he noted.
He stated that being one of Nigeria's critical cargoes, Nigeria hopes to compete with the Philippines in provision of seafarers, noting, however, that the country also faces challenges.
He praised the book for its straightforward narrative that makes it easy for every scholar to understand how Dakuku's team applied leadership and management principles to change the maritime industry in Nigeria.
Bellamy is a professor emeritus of Maritime Security at the University of Greenwich, United Kingdom and a former professor of Military Science and doctrine at Cranfield University.
He's also the editor-in-chief, International Journal of Maritime Crime and Security.
Previous articleWe'll Intensify Human Capital Devt Drive, Says Buhari
Next articleIndia Firm, TCN in Trouble over $24.705m Contract
Nigerian Breweries Donates N48m Equipment to UBTH Neo-Natal Unit
MTN Nigeria Hails Super Eagles' Second Round Progression
Youths Empowerment, Gender Inclusion, Our Major Focus, Says Kwara Gov
Nigeria Lost over N10tn to Twitter Ban, LCCI Claims


text:
Indonesia: Five Imprisoned in Wake of Muslim Mob Violence
Five Indonesians have been sentenced to prison in connection with violent rioting that destroyed or damaged at least 50 churches and killed several Christians.
Indonesian authorities report that, in all, 50 individuals have been arrested on charges associated with the most recent surge of rioting, starting in June 1996 and continuing this year (CT, March 3, 1997, p. 50). The five who have been convicted were sentenced to one to five months in prison.
Meanwhile, provincial governments have provided financial aid for rebuilding churches. Additionally, Abdurahman Wahid, as head of Indonesia's most prominent Muslim group, Nahdlatul Ulama, has taken "moral responsibility" for the violent incidents because many rioters likely belonged to the group.
In a related development, youth leaders, including Christians, Muslims, and Hindus, have formed the Nationality Forum for Indonesian Youth, which has the enhancing of cooperation and communication among religious groups as a primary goal.
TENSION PERSISTS: Nevertheless, rioting has not fully ended. On June 15 on the island of Madura in East Java province, rioters burned shops, a movie theater, a church, and a Buddhist temple in Bangkalan. The Madurese ethnic group is known for provincial attitudes and staunch adherence to Islam. But many observers consider Indonesia's uncertain and tense political circumstances at least as significant a factor as religious or ethnic feelings.
The May 29 general election, won handily—and, many assert, fraudulently—by the ruling Golkar party, was the most violent in Indonesia's history.
Supporters of the country's only two legal opposition parties, and others holding antigovernment views, are systematically excluded from political decision making and sometimes harassed and persecuted.
In Bangkalan, a local leader in the Muslim-oriented United Development party said, "There is still concern among the population over widespread violations and fraud during the elections, but officials are just having fun and being merry. [The people] just felt insulted."
As the 30-year authoritarian rule of President Suharto, now 76, enters its final chapters, social tensions between ethnic and religious groups are surfacing more frequently. Indonesia's last political transition three decades ago witnessed a blood bath in which 500,000 people died.
In addition to identifiably religious unrest, the May election also saw a string of unprecedented bold attacks on polling stations and military targets by separatist rebels in the majority Roman Catholic province of East Timor, forcibly annexed by Indonesia in the mid-1970s.
Religious tensions in East Timor have flared over allegations that Indonesian authorities are attempting to "Islamize" the region by encouraging Muslims to migrate to East Timor from other Indonesian islands.
MUSLIMS, CHRISTIANS CLASH: In Rengasdengklok, 40 miles northeast of Indonesia's capital, Jakarta, Muslim resentment toward Christians has been fueled in part by the recent renovation and expansion of a Presbyterian church. Also, a Chinese Christian businessman has constructed a religious monument, representing a fish, the enduring symbol of early Christianity.
In January, rioters in Rengasdengklok destroyed churches, Buddhist temples, and shops owned by the largely Christian—and relatively prosperous—ethnic-Chinese minority in Rengasdengklok. The riot began after a Chinese businessman scolded a Muslim teenager for playing a drum in early morning hours as part of traditional activities for the fasting month of Ramadan.
"Religious believers here had lived harmoniously," a Muslim imam told the Bangkok-based newspaper The Nation. "We had never had a problem before." During the riot, local Muslims spray-painted the word Muslim on their houses and shops.
Some Muslims also painted the word on their Christian neighbors' property, in a bid to protect them. "My Muslim neighbor threw her sajadah [Muslim prayer rug] into my living room," one ethnic-Chinese woman said. "It did not help, actually. The rioters still destroyed my house. But I will never forget her help."
September 1 1997, Vol. 41, No. 10, Pg 80
This article is from the September 1 1997 issue.


text:
Ка́рлос Фари́ньяс Канте́ро (; 28 ноября 1934, Сьенфуэгос, Куба — 30 июня 2002, Гавана, Куба) — кубинский композитор, дирижёр и педагог.

Биография
Окончил Муниципальную консерваторию в Гаване, где учился у Арольда Граматхеса, Серафина Про, Эдгардо Мартина, Архельерса Леона, Хосе Ардеволя (композиция, музыкально-теоретические дисциплины) и Энрике Гонсалеса Мантичи (дирижирование). В 1956 году продолжил обучение у Аарона Копленда в Тэнглвудском музыкальном центре, а в 1961—1963 годах совершенствовался в Московской консерватории у Александра Пирумова и Дмитрия Кабалевского. С 1967 года возглавлял музыкальный отдел Национальной библиотеки. В 1950-х—начале 1960-х годов творчество было вполне традиционно, но позже стал экспериментировать в области алеаторики, сонорики, а также с комбинациями звуковых и визуальных выразительных средств. Писал музыку для кино.

Сочинения
 «Тьенто II» для 2 фортепиано и ударно-шумовой группы / Tiento II (1969)
 «Рельефы» для 5 групп инструментов и сирены / Relieves (1969)
 «Диалоги» II и III / Diálogos (1972)
 балет «Пробуждение» / Despertar (1960)
 балет «Свершение истории» / Hecho historia (1973)
 балет «Ягрума» / Yagruma (1975)
 вариации для оркестра (1955)
 ноктюрн для оркестра (1957)
 «Стены, решётки и витражи» для оркестра / Muros, rejas y vitrales (посвящён памяти художницы Амелии Пелаэс, 1970)
 концерт для скрипки и ударных (1976)
 произведения для фортепиано
 произведения для гитары

Фильмография
  — Истории революции / Historias de la revolución (реж. Томас Гутьеррес Алеа)
  — Я — Куба / Soy Cuba (реж. Михаил Калатозов)
  — Мелья: Хроника борьбы / Mella (реж. Энрике Пинеда Барнет)
  — Портрет Тересы / Retrato de Teresa (реж. Пастор Вега)
  — Хабанера / Habanera (реж. Пастор Вега)
  — Барагуа / Baragua (реж. Хосе Массип)
  —  / En el aire  (реж. Пастор Вега)
  — Исабель де Обальдиа / Isabel de Obaldía (реж. Питука Ортега-Эйльброн)
  — Опыт инвентаризации / Inventario de una experiencia (к/м, реж. Эдгар Соберон Торчиа, Панама)

Литература
 Музыкальный энциклопедический словарь / Гл. ред. Г. В. Келдыш. — М.: Советская энциклопедия, 1990. — с. 571 — ISBN 5-85270-033-9

Примечания

Ссылки
 Карлос Фариньяс на Allmusic

 Карлос Фариньяс на сайте КиноПоиск

Балетные композиторы Кубы


text:
bow animal crossing
The bow measures about 3 inches by 2 inches. His name and design are based on the BowLingual translation device which translates dog sounds into distinct emotions that can be understood by humans. In order to try out something new, you'll first need to acquire a mirror. He dreams of becoming a translator someday. She has whiskers and her paws are all pink. Bow has brown ears, and a green face representing a monochrome LCD screen. Most orders are shipped 5 to 7 days, but processing time will not be more than 1 to 2 weeks. For more information, click here. He is very similar in name and appearance to Meow. Bow can only move into a town after scanning his e-Reader card, which was exclusively bundled with Doubutsu no Mori e+ Figurine Series 48. バウBauBowUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknown, From Nookipedia, the Animal Crossing wiki, For more images, view this subject's gallery, https://dodo.ac/np/images/a/ae/Bow_DnMe%2B.png, https://nookipedia.com/w/index.php?title=Bow&oldid=460207. The digging tool has been a staple in the game series … The tips of his paws are white and brown and his stomach is white. Bow is a lazy dog villager in Doubutsu no Mori e+. Gender He will get along with other lazy villagers with whom he will talk about food, comics, or superheroes. She has a similar appearance to Bow the dog, since they both look like they have monochrome LCD screens on their faces. Meow and Bow instead have faces designed to resemble monochrome LCD screens, with the outside of their faces both having a button or logo placed on their forehead. August 3rd (Leo) Bow can help with that. Bow is a yellow dog that is similar in appearance to Meow the cat. It is connected to a 2 inch metal clip. AFe+ I'll probably eat dinner again after it's over." Bow will get along well with other villagers, but may offend or confuse jock villagers, who have a lifestyle of exercise and fitness, which conflicts with the lazy lifestyle of relaxing and food. Her and Bow seem to be based on the Meowlingual and Bowlingual, respectively. He and Meow are based on the Bowlingual and Meowlingual devices. [citation needed]. Sprocket and Ribbot are more similar to the gene… Bow is a lazy villager, which means he will enjoy sleeping and eating. Dog Pattern Placement will vary. He will also get along well with normal, peppy, smug and sisterly villagers, and occasionally cranky villagers, but may from time to time annoy snooty villagers, who disagree with the lazy lifestyle. He could only move into a village if the player has his e-reader card. K.K. The most popular color? Perfect for journals, planners, travelers notebooks or gift. Personality Below is a brief description of the lazy personality. The tips of Bow's paws are white and brown and his stomach is also white. Animal Crossing Wiki is a FANDOM Games Community. Well you're in luck, because here they come. Animal Crossing isn't the most forthright in telling you how to change the look of your character. This listing for a Animal Crossing theme bow planner clip. Just keep visiting your villages and you might find them crafting and get them to share a DIY recipe with you. "I think I'll eat dinner before I go stake out a spot. As a lazy villager, Bow will be friendly and easy to get along with due to his laid back lifestyle. Species bow You want to properly convey your feelings to someone you love? Bow is a yellow dog that is similar in appearance to Meow the cat. The Animal Crossing: New Horizons shovel isn't as quickly accessible as you might expect. She has a green face and a pink head with pink ears. Birthday You guessed it: green. Like all lazy villagers, he has a love of food and relaxing. Villagers only appearing up to Animal Forest e+, https://animalcrossing.fandom.com/wiki/Bow?oldid=523607. He will enjoy partaking in the usual hobbies, usually for relaxing reasons or for food, like when fishing. An unknown logo can be seen on Bow's forehead. Bow, Meow, Sprocket and Ribbot are all robot villagers. Appearance [edit | edit source] Bow is a yellow dog that is similar in appearance to Meow the cat. Bow, Meow, Sprocket and Ribbot are all robot villagers. He's a powerful ally. The clothing Bow originally sports is the Houndstooth Knit. Bow (バウ) is a lazy, dog villager from the Animal Crossing series, only appearing in Animal Forest e+. His name comes from "Bow-wow", a sound that dogs are considered to make in popular culture. He and Meow are based on the Bowlingual and Meowlingual devices. Bow is a yellow dog with brown ears and a green face. An unknown logo can be seen on Bow's forehead. The clothing Bow originally sports is the Houndstooth Knit. Did you scroll all this way to get facts about animal crossing bow? Once your order has been processed within the current processing times of the shop. is a lazy dog villager from the Animal Crossing series, only appearing in Animal Forest e+. There are 215 animal crossing bow for sale on Etsy, and they cost $5.82 on average. His feline counterpart is Meow, whose name and design is based on a similar translation device for cats, called the MeowLingual. Male Bow has brown ears and a green face. Appearances It also sounds like "bow" as in "bow-wow", an onomatopoeia for a dog's barking. It is possible that Bow's name comes from "Bow-wow" a sound that dogs make when they howl. Initial phrase The most common animal crossing bow material is plastic. Meow is a pink cat that initially wears the blossom shirt. Sprocket and Ribbot are more similar to the general pop culture depiction of robots, with obvious mechanical parts and visible screws.
Outback Sweet Potato Fries Recipe, Under Seat Subwoofer Pros And Cons, Bicep Size For Height, How Many Scoville Units Is A Carolina Reaper, Thermos Teapot With Infuser,
bow animal crossing 2020


text:
Prague. The Charles Bridge. Hradčany View
Czech Republic/
A webcam with a splendid panorama view located at the Pachtuv Palace hotel will let you enjoy several sights of Prague at once. You'll go for a virtual walk across sights such as: Prague Castle, Saint Vitus Cathedral, the Charles Bridge, the Novotny footbridge, Petřín Lookout Tower, the Church of Saint Nicholas, Loreta, Kampa and the Church of Our Lady Victorious.
The Guinness World Records say that Prague Castle is the biggest castle in the world. Traditionally, Prague Castle was the residence of the Czech leadership and now it's the residence of the Czech Republic president. The castle complex includes Saint Vitus Cathedral – a true architectural masterpiece, it's one of the most beautiful and oldest cathedrals in Europe.
Charles Bridge is the oldest bridge across the Vltava River and the second oldest bridge in Czech Republic. Nowadays, it's occupied by street traders, artists and musicians. Regardless of the weather, the bridge is full with crowds of tourists because it's a real open air museum. The main points of interest of the bridge are thirty sculptures that tell you about historic events of the country. The John Nepomucene sculpture is the most reputed and well-known. People say a wish will definitely come true if one touches this sculpture. No wonder parts of the sculpture are polished till they shine.
The Novotny footbridge is located on the right bank of the Vltava River. On the bridge is the Old Town Water Tower.
The Petřín Lookout Tower can also be called the younger sister of the Eiffel Tower. It has two viewpoints from where the whole Czech capital can be observed.
The Church of Saint Nicholas is a monumental building on the Lesser Town Square built in Baroque style.
Loreta is an abbey complex, the central construction of which is the Holy Hut – a construction that represents the hut in Nazareth where Lady Mary lived with the Christ child. The complex also includes the church of the Lord's Birth, a cloister and treasury.
Kampa is Prague's Venice. It's a small island on the Vltava River which is separated from land by the Chertovka River. One can get there by crossing the Charles Bridge. Kampa is a very beautiful and calm place in the middle of the capital city.
The Church of Our Lady Victorious is well known for the Infant Jesus – a wax-coated wooden statue regarded as the main catholic relic of the Czech Republic.
Prague. The Prague Castle and The Charles Bridge
Prague. Charles Bridge. View to the Prague Castle
Prague. Kavčí Hory


Dance Central 3 will be boasting a bonkers storyline...much like the previous two games. In DC3, players will meet the Dance Central Intelligence crew, who are time travelling detectives who investigate dance crimes.
"Prepare for time travel in the newly revealed Story mode of Dance Central 3," says the blurb. "Played solo or with a friend, players will join the ranks of Dance Central Intelligence (DCI) to uncover a plot to destroy Dance Central and journey through time to learn iconic dance moves from the '70s, '80s, '90s, '00s and beyond.
Ciara ft. Missy Elliott – "1, 2 Step"


text:
Stamatis Gonidis
Stamatis Gonidis was born in 16 September 1957 in a Greek Aegean island, named KYTHNOS.
In young age, Stamatis Gonidis decides to leave the island and become a sailor. During his travels around the world, in his free time he wrote songs, and he sung them to his colleagues.
Everyone liked his songs and his colleagues were those to support him and persuaded him to become a singer.
By then Stamatis Gonidis starts to sing professionally, and his first personal album does not take a long time to come.
After that a career full of gold and platinum albums comes and makes Stamatis Gonidis one of the most popular singers in Greece. Stamatis Gonidis in his songs has sung the love, the pain, the happiness.
In December 2000, Stamatis Gonidis made his own wine, named "Saint", which is given only to his friends.
In 2001, Stamatis Gonidis, decided to published a book, entitled "The flying Rabbit", which is a fairy tale for grown up kids.


text:
Dr Mehmet Oz Net Worth
in Richest Business
Dr Oz Net Worth:
Dr Oz's Salary:
Salary: $20 Million
Date of Birth: Jun 11, 1960 (62 years old)
Place of Birth: Cleveland
Height: 6 ft (1.85 m)
Profession: Physician, Writer, Surgeon, Author, Scientist, Cardiac surgeon, Talk show host, Television producer
What is Dr. Mehmet Oz's Net Worth and Salary?
Dr. Mehmet Oz is a Turkish-American cardiothoracic surgeon, author, and television personality who has a net worth of $200 million. In May 2022, Oz submitted a financial disclosure as part of his Pennsylvania Senate campaign. According to his financial disclosure, Dr. Oz and his wife Lisa control assets that are valued between $104 and $422 million.
Dr. Oz is most widely-known for his syndicated TV series, "The Dr. Oz Show," which was launched in 2009 by Oprah Winfrey's Harpo Productions and Sony Pictures. Oz has written several books with Michael F. Roizen, including "YOU: The Owner's Manual: An Insider's Guide to the Body that Will Make You Healthier and Younger" (2005), "YOU: On a Diet: The Owner's Manual for Waist Management" (2006), and "YOU: Having a Baby: The Owner's Manual from Conception to Delivery and More" (2009), and he is also the author of "Healing from the Heart: A Leading Surgeon Combines Eastern and Western Traditions to Create the Medicine of the Future" (1999) and "Food Can Fix It: The Superfood Switch to Fight Fat, Defy Aging, and Eat Your Way Healthy" (2017).
Dr. Oz got his big break in television on "The Oprah Winfrey Show" in 2004 and later appeared on "Larry King Live" as well as other TV programs. The World Economic Forum named Dr. Oz a "Global Leader of Tomorrow" from 1999 to 2004, and he was included on "Time" magazine's "100 Most Influential People" list in 2008.
In November 2021, Dr. Oz announced his intention to run for an open Senate seat in Pennsylvania. That campaign was marked by a number of social media blunders that made Oz look somewhat foolish and out-of-touch. His campaign has also been criticized because Oz has spent much of the last few decades of his life as a permanent resident of New Jersey with vacation homes in Florida. He reportedly did not buy his own property in Pennsylvania until December 2021. More details on Oz's 10 homes in the "Real Estate" section of this article.
💰 Compare Dr Oz's Net Worth
Mehmet Oz was born Mehmet Cengiz Öz on June 11, 1960, in Cleveland, Ohio. His parents, Suna and Mustafa, emigrated from Turkey, and Mehmet grew up with two sisters, Nazlim and Seval, in a mixed Muslim household (traditional on his father's side, secular on his mother's side). He attended Tower Hill School in Wilmington, Delaware, then earned a degree in biology from Harvard University in 1982. Oz played on Harvard's football team, and he helped the water polo team win an intramural college championship.
In 1986, he earned an MD from the University of Pennsylvania School of Medicine and an MBA from Penn's Wharton School. Mehmet received the Captain's Athletic Award in college, and as a medical student, he was class president and later became student body president.
Mehmet's father spent many years serving as the Medical Center of Delaware's chief of thoracic surgery, and after he passed away in 2019, Oz wrote on social media, "I remember as a child running behind his fast-moving legs while he made hospital rounds…I fell in love with medicine after witnessing my dad do sometimes painful procedures on desperately sick patients who subsequently thanked him for saving their lives."
Dr. Oz founded New York-Presbyterian Hospital's Cardiovascular Institute and Integrative Medicine Program in 1994. In 1996, fellow cardiothoracic surgeon Ottavio Alfieri proposed that only one suture may be needed to close a mitral valve leak, leading Mehmet to come up with the idea to put one staple in using a catheter. This resulted in Oz and his colleagues at Columbia University patenting a device called MitraClip in 1997. In 2010, he co-founded the health and wellness company Sharecare, Inc. with Jeff Arnold, who founded WebMD. In 2001, Mehmet became a professor at Columbia University, teaching in the Department of Surgery, and he is the vice-chairman of the university's College of Physicians & Surgeons. After making numerous appearances on "The Oprah Winfrey Show" for five seasons, Winfrey began producing "The Dr. Oz Show" through her production company. The show premiered on September 14, 2009, and it has aired more than 1,500 episodes as of this writing. In 2011, Mehmet appeared on "Ask Oprah's All-Stars" on OWN, and three years later, the network aired a 10-episode documentary series entitled "Surgeon Oz."
In 2018, Mehmet was appointed to the President's Council on Sports, Fitness, and Nutrition, and in 2020, he was appointed to a second term. In March 2021, Mehmet began a two-week stint as a guest host on "Jeopardy!," leading more than 500 past contestants to sign a letter stating that Dr. Oz shouldn't host a "show that values facts and knowledge" because "he has used his authority as a doctor to push harmful ideas onto the American public, in stark contrast with his oath to first do no harm." Mehmet is the author of several "New York Times" bestsellers, and he has written for "Esquire" and "O, The Oprah Magazine." He received the 2009 National Magazine Award for Personal Service for his article "Retool, Reboot, and Rebuild," and the magazine "Dr. Oz The Good Life" launched in 2014.
(Photo by Robin Marchant/Getty Images)
Mehmet married Lisa Lemole on June 29, 1985, and they have four children together, Daphne, Arabella, Zoe, and Oliver. Daphne, their eldest daughter, is an author and television host. Mehmet and Lisa founded the non-profit organization HealthCorps, which is dedicated to peer mentoring and health education. Oz is a citizen of both America and Turkey and speaks English and Turkish fluently. He is a practicing Muslim and a proponent of transcendental meditation. In 2010, Mehmet underwent a routine colonoscopy for his show and a pre-cancerous polyp was discovered in his intestine. Of the experience, he stated, "The only thing holding me back from a terrible outcome is the dumb luck that I checked myself out for the show. I would have put this off, like a lot of people. But I bet this saved my life." In 2019, Oz played in the NBA All-Star Celebrity Game in Charlotte, North Carolina, and the All-Star Legends & Celebrity Softball Game in Cleveland, Ohio.
In 2014, a team of medical researchers examined Dr. Oz's advice/claims and reported that as much as 60% of said advice had no scientific basis at all.
"The Dr. Oz Show" has earned 19 Daytime Emmy nominations, winning Outstanding Talk Show Host in 2010, 2011, and 2014, Outstanding Informative Talk Show Host in 2016, and Outstanding Talk Show/Informative in 2011, 2012, 2013, 2017, and 2018. He also received a People's Choice Award nomination for Favorite Daytime TV Host in 2016.
During the course of his PA Senate campaign, it was revealed that Dr. Oz and his wife own approximately TEN homes.
New York and New Jersey:
Oz and Lisa's longtime primary home for the last few decades has been a 9,000 square foot home in Cliffside Park, New Jersey. Mehmet and Lisa paid $750,000 the home in 2000. Today the home is worth around $3 million based on recent comparable sales. Separately from Oz, Lisa and her family own the home directly next door to this New Jersey mansion.
Oz's financial disclosure shows the he and Lisa own a condo in New Jersey and two condos in New York City.
In 2015, Dr. Oz paid $18 million for a lavish 12,000 square foot oceanfront home in Palm Beach, Florida. Oz and Lisa proceeded to spend a reported $3.4 million on renovations to the home between March 2018 and September 2020. The completed home has 10 bedrooms, 15 bathrooms, a renovated pool, an outdoor spa, a game room and more. The appraised value of the home is $25 million, but according to Zillow the home is worth $50 million today.
When he is not using the home Oz rents it out for as much as $275,000 per month. According to his Senate financial disclosure, this home generates $1-5 million per year in annual income.
Here is a video of the property from 2014 when it was originally listed for $22 million:
In December of 2021, Oz bought three parcels of land in Okeechobee County, Florida for a total of $6.5 million. The land is a cattle farm.
According to his financial disclosure he owns financial stakes in four hotels in Florida. He estimated the combined value of these stakes at $800,000.
Pennsylvania:
As he prepared to campaign for an open Senate seat in Pennsylvania, Oz realized it might help to actually LIVE IN PENNSYLVANIA. Therefore, in 2020 Oz and Lisa moved into Lisa's parents' home in the town of Bryn Athyn, PA. In December 2021 Oz and Lisa paid $3.1 million for a 34-acre property featuring a 7,000 square-foot mansion in the same town. However, he did not move into his new home right away and was not living there during much of his campaign. Right after acquiring the property, Oz and Lisa began a massive renovation.
Turkey:
In his parents' native Turkey, Dr. Oz owns two residential estates and a third property which is currently rented out as a student dormitory.
Maine:
Separately from Oz, Lisa and her family own a mansion in Maine.
Senate Candidate Dr. Oz Reveals $100 – $400 Million Personal Fortune. Would Make Him One Of The Very Richest Members Of Congress
Andrew Weil Net Worth
Oprah Winfrey Net Worth
Donald Trump Net Worth
Jill Biden Net Worth
Regis Philbin Net Worth
Nate Berkus Net Worth
Dr. Ben Carson Net Worth